Excellent outcome of children/adolescents with primary mediastinal large B-cell lymphoma treated with a FAB/ LMB-based chemotherapy regimen with rituximab.

IF 8.2 1区医学 Q1 HEMATOLOGY Haematologica Pub Date : 2024-11-01 DOI:10.3324/haematol.2024.285403

Marie Emilie Dourthe, Anne Auperin, Charlotte Rigaud, Melissa Barbati, Jacinthe Bonneau, Nimrod Buchbinder, Marie-Laure Couec, Peggy Dartigues, Stéphane Ducassou, Nathalie Garnier, Stéphanie Haouy, Bénédicte Jonca, Anne Jourdain, Amaury Leruste, Thierry Molina, Françoise Montravers, Marlène Pasquet, Aurélie Phulpin, Maryline Poirée, Mathieu Simonin, Alexandra Spiegel, Arnauld Verschuur, Thierry Leblanc, Judith Landman-Parker, Catherine Patte, Véronique Minard-Colin

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

以FAB/LMB为基础的化疗方案联合利妥昔单抗治疗原发性纵隔大B细胞淋巴瘤的儿童/青少年疗效极佳。

不详。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.